A pharmacovigilance analysis using data from the FDA's Adverse Event Reporting System identified a statistically significant association between GLP-1 RAs and the onset of headache, with a reporting odds ratio (ROR) of 1.74, and migraine (ROR: 1.28), suggesting that these symptoms can develop regardless of pre-existing headache diagnoses.17, 35Therefore, careful clinical monitoring is warranted, especially during the early phases of treatment. The gene discussed is GLP1R; the disease is migraine disorder.